FUNDAMENTAL AND CLINICAL EVALUATION OF KW-1100 (BACMECILLINAM) IN THE FIELD OF UROLOGY

• Published in: CHEMOTHERAPY Vol. 33; no. Supplement3; pp. 276 - 288
• Main Authors: HARADA, MASUYOSHI, FUJII, AKIRA, YASUNO, HIROHIKO, TADERA, SHIGENORI, ARAKAWA, SOICHI, KATAOKA, NOBUMASA, KAMIDONO, SADAO, ISHIGAMI, JOJI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1985
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.33.Supplement3_276

Distribution of KW-1100, a new oral penicillin agent, in human was studied by measuring KW-1100 levels in the serum and urine in 6 healthy adult volunteers received either type of capsules with different of this drug and the usefulness of this drug against various infections in the field of urology was evaluated. The mean peak serum level of KW-1100 an hour after oral administration of two 40mg capsules and one 80 mg capsule in the fasting state measured by cross over method was 1.53μg/ml and 1.57μg/ml. Peak level of KW-1100 in urine was obtained in 0-2 hr portion of urine in both formulations. The mean level was 340.7μg/ml in the 40 mg-capsule and 510.3μg/ml in the 80mg-capsule. Recovery rate of the drug in urine to the total dose within 6 hours after the administration was 55.2% in the former and 55.0% in the latter. The clinical results were excellent in 7 cases and moderate in 6 cases out of 13 patients with acute uncomplicated cystitis, with the effectiveness rate of 100%, and excellent in a case and moderate in 2 cases out of 10 patients with complicated urinary tract infection, with the effectiveness rate of 30%. Neither adverse effects nor abnormal laboratory findings were observed.